Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

CordenPharma pursues continuous peptide manufacturing

by Rick Mullin
January 23, 2022 | A version of this story appeared in Volume 100, Issue 3

 

A photo of a technician overseeing the operation of pharmaceutical equipment.
Credit: CordenPharma
Peptide elongation monitoring using PeptiSystem equipment

CordenPharma says it is implementing continuous process manufacturing of peptides at its plant in Frankfurt, Germany, in collaboration with PeptiSystems, a Swedish developer of manufacturing instruments for peptides and oligonucleotides. The project aims to reduce solvent consumption in solid-phase peptide synthesis by at least 40% from current batch production methods. CordenPharma also hopes to cut the time for large-scale synthesis by as much as 90%.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.